Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage
- Authors
- Sung, Hwa Jung; Lee, Se Ryeon; Choi, In Keun; Park, Yong; Choi, Chul Won; Kim, Hyeoung-Joon; Yhim, Ho-Young; Kim, Byung Soo
- Issue Date
- 2015
- Publisher
- KARGER
- Keywords
- Chronic myelogenous leukemia; Imatinib mesylate; Body surface area; Complete cytogenetic response
- Citation
- ACTA HAEMATOLOGICA, v.134, no.1, pp.59 - 68
- Indexed
- SCIE
SCOPUS
- Journal Title
- ACTA HAEMATOLOGICA
- Volume
- 134
- Number
- 1
- Start Page
- 59
- End Page
- 68
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/96128
- DOI
- 10.1159/000369444
- ISSN
- 0001-5792
- Abstract
- Aim: Chronic myelogenous leukemia (CML) chronic phase (CP) patients cannot tolerate a standard dose (400 mg/day) of imatinib mesylate (IM), sometimes needing a reduced dose. This study aimed to find convenient clinical indexes, rather than plasma trough levels of IM, to define the appropriate IM dosage. Methods: Seventy CML CP patients who experienced an IM dose reduction, or a temporary cessation, were enrolled from 2002 to 2010. The IM treatment was resumed and maintained at either >= 400 mg in 25 patients (35.7%; group >= 400 mg) or at <= 300 mg in 45 patients (64.3%; group <= 300 mg). The various clinical characteristics of these patients were evaluated. The plasma trough level of IM was monitored in 20 patients from group <= 300 mg. Results: Via multivariate analysis, the IM dosage divided by the body surface area (BSA) was an important index, presupposing a complete cytogenetic response at 12 months (CCyR12). Patients with IM/BSA >206.7 mg/m(2) showed a higher probability of CCyR12 than others. The IM/BSA (221.7 mg/m(2)) in group <= 300 mg was higher than in group >= 400 mg (207.6 mg/m(2)). The sustained response and survival rate of group <= 300 mg was comparable to that of group >= 400 mg. The plasma trough level of IM was significantly correlated with the IM/BSA. Conclusion: Our study suggests that IM dose adjustments, based on IM/BSA, could improve the clinical outcomes in CML CP patients. (C) 2015 S. Karger AG, Basel
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
- Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.